1
The genetic problem
In limb-girdle muscular dystrophy (LGMD), a change in a gene means the body makes too little or no functional protein. Over time, this can lead to weaker muscles.
The fundamental idea is simple: correct, replace, silence, or supplement faulty genes that cause disease. What once faced major technical and safety challenges has now resulted in approved therapies for several rare diseases and growing optimism for many others.
The gene therapy sector has grown by a factor of 10 to 15 in the space of about ten years. We now have approved gene therapies for conditions such as SMA, inherited blindness, haemophilia, sickle cell disease, and certain forms of cancer. We have hundreds of clinical trials for rare genetic disorders, and a manufacturing, regulatory, and clinical infrastructure that barely existed a decade ago.
The challenge is no longer whether gene therapy can work, but how we can bring promising therapies for LGMD to patients as quickly as possible.
How gene therapy can make a difference
A new approach. Real hope for people with limb-girdle muscular dystrophy.
2
A working gene as a therapy
Gene therapy delivers a healthy copy of the gene to give cells the instructions to make the missing protein again.
3
A vector as a delivery vehicle
The healthy gene is packaged into a harmless virus, called a vector, that can deliver the gene to muscle cells.
4
Delivery to muscle cells
The vector is given (for example by an infusion) and travels through the body to muscle tissue, where it delivers the healthy gene into cells.
5
Functional protein and stronger muscles
Muscle cells use the new gene instructions to make the functional protein. This can help muscles work better and may slow or stop further muscle loss.
From research to real life
Gene therapy goes through careful research, testing and clinical trials to make sure it is safe and can help people. It takes time, but it brings us closer to new treatment options.
Research
Understanding the disease and developing a therapy.
Preclinical testing
Checking safety and effectiveness in the lab.
Clinical trials
Testing in people, in phases.
A brighter future
Support our missionToday's gene therapy approaches
Today, gene therapy approaches fall into three categories:
Approach 1
Gene replacement
Delivering a healthy copy of a missing or defective gene.
Approach 2
Gene editing
Directly correcting mutations using technologies such as CRISPR.
Approach 3
Gene modulation
Increasing, decreasing, or altering gene expression.
Landmark approvals
Several landmark approvals have demonstrated the potential of gene therapy:
Luxturna
Restored functional vision in patients with inherited blindness.
Zolgensma
Transformed outcomes for infants with spinal muscular atrophy (SMA).
Blood & immune disorders
Gene therapies for hemophilia, beta-thalassemia, sickle cell disease, and certain immunodeficiencies have shown that one-time treatments can provide years of clinical benefit.
As a result, gene therapy is increasingly viewed not merely as symptom management, but as a pathway toward disease modification and potentially long-term correction of genetic disorders.
Why neuromuscular diseases are ideal targets
Neuromuscular diseases are among the most promising targets for gene therapy because many are caused by mutations in a single gene. Once the genetic defect is identified, researchers can design therapies aimed at addressing the root cause rather than treating symptoms.
Several factors have accelerated progress: advances in genetic testing have improved diagnosis; improved genetic carriers (also called viral vectors or AAVs) can efficiently target muscle tissue; there is greater insight into disease progression; and international patient registries have enabled clinical trials in rare diseases. The most commonly used delivery vehicles are adeno-associated viruses (AAVs), which can transport therapeutic genes into muscle cells and, in some cases, motor neurons.
Successes in neuromuscular disorders
Spinal Muscular Atrophy (SMA)
The greatest success story to date is SMA. Patients with SMA lack a functional SMN1 gene, leading to progressive muscle weakness and often death in infancy. Gene therapy has fundamentally changed the outlook for many affected children. Zolgensma delivers a working copy of the SMN1 gene through a single intravenous infusion. Children treated early can achieve developmental milestones that were previously unimaginable, including sitting, standing, and in some cases walking independently. SMA demonstrated for the first time that systemic gene therapy could successfully target a neuromuscular disease throughout the body.
Duchenne Muscular Dystrophy (DMD)
DMD has become another major focus of gene therapy research. The dystrophin gene is too large to fit into standard AAV vectors, so researchers developed "micro-dystrophin" therapies containing a shortened but functional version of the gene. Several clinical trials have demonstrated production of micro-dystrophin protein in muscle tissue, improvements in biomarkers, and evidence of slower disease progression. Although challenges remain regarding long-term durability, it has been shown that gene therapy can target even very large muscle diseases.
